0000000000662681

AUTHOR

Chiara Intrivici

Pegylated liposomal doxorubicin (PLD) and weekly paclitaxel (P) as second line chemotherapy in metastatic bladder cancer.

research product

Gemcitabine plus metronoic capecitabine as second/third line chemotherapy in advanced adrenocortical carcinoma. A multicenter phase II trial.

research product

The use of pegylated liposomal doxorubicin (PLD) in association with weekly paclitaxel as second line therapy in metastatic bladder carcinoma: final results

research product

Low dose oral chemotherapy for hormone refractory prostate carcinoma estramustine phosphate versus estramustine phosphate and etoposide. A Randomized phase II study of GSTU foundation

research product

“Serum HER-2/neu (s-HER2) levels evaluation in breast cancer (BC) patients (PTS)”

research product

The use of somatostatin analogues in metastatic hormone refractory and chemo resistant prostate cancer with neuroendocrine differentiation.

research product

A case report of inflammatory pseudotumor of the liver

research product

Pegylated Liposomal Doxorubicin and weekly paclitaxel as first line treatment in metastatic breast cancer

research product

Weekly Paclitaxel (T) and pegylated liposomal Doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patients.VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004

research product

Antifungal prophylaxis of oropharyngeal mucositis with itraconazole during adjuvant chemotherapy in colorectal cancer (CRC)patients.

research product

La terapia adiuvante nel carcinoma del colon: un update della lettaratura

research product